Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis

Tinea Corporis Clinical Trial

Official title:
A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis

Status Completed

Clinical Trial Summary

The objective of this study was to evaluate the safety, efficacy, and pharmacokinetics of luliconazole cream 1% when applied topically for 7 days in pediatric participants 2 years to 17 years of age (inclusive) with tinea corporis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02767947
Study type	Interventional
Source	Bausch Health Americas, Inc.
Contact
Status	Completed
Phase	Phase 4
Start date	February 8, 2016
Completion date	September 22, 2016

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05881980` - Efficacy and Safety of Terbinafine and Itraconazole	Phase 2/Phase 3
Completed	`NCT01349998` - Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis	Phase 3
Completed	`NCT02466867` - An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis	Phase 4
Completed	`NCT02227290` - Pediatric Subjects With Tinea Corporis	Phase 4
Not yet recruiting	`NCT01105013` - Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections	Phase 3